Javascript must be enabled to continue!
Antiviral Potential of Lauric Acid against Dengue Virus 2: Evidence from a Luciferase-Based Replicon Assay
View through CrossRef
ABSTRACT
Dengue virus (DENV) infection generates a significant health burden throughout the world, and there are no clinically approved antiviral drugs, as of now. The virus also depends on lipid metabolism in the host to conduct effective replication and this makes lipid-directed compounds promising as therapeutic options. We assessed the antiviral effect of lauric acid, a 12-carbon medium-chain fatty acid, against DENV serotype 2 (DV2) in the presence of a stable cell line, DV2-replicon, expressing all the non-structural proteins (NS1-NS5) and a luciferase reporter. Active viral replication in replicon cells was established by morphological examination and immunofluorescence of cells. The MTT assay was used to determine the cytotoxicity of lauric acid revealing the LD50 of 2.52 uM, so higher concentrations were toxic as the effect of the drug is dose-related. The antiviral effect was tested through replicon inhibition (luciferase) assay which showed an incredible inhibition of viral RNA replication with a IC50 of 1.70 uM and this is equivalent to antiviral mycophenolphycic acid. The cytopathic effects, as well as a decrease in the activity of luciferase, proved the presence of viral translation and replication inhibition within the process of the treatment of the lauric acid. These results propose that lauric acid has cytotoxic and antiviral dual effect and can be a possible inhibitor of DENV replication. The toxicity needs to be reduced and future research is necessary to explain its molecular pathway and also to come up with the best delivery methods.
IMPORTANCE
Dengue virus (DENV) remains a significant health challenge to the world since there are no effective antiviral agents. This work will recognize lauric acid as a possible dengue virus replication inhibitor in a model of a DV2 replicon, exhibiting antiviral action that is similar to that of mycophenolic acid. These results support lipid-directed compounds as potential dengue antiviral targets, but more research is needed to minimize toxicity and better understand the molecular mechanism of action.
Title: Antiviral Potential of Lauric Acid against Dengue Virus 2: Evidence from a Luciferase-Based Replicon Assay
Description:
ABSTRACT
Dengue virus (DENV) infection generates a significant health burden throughout the world, and there are no clinically approved antiviral drugs, as of now.
The virus also depends on lipid metabolism in the host to conduct effective replication and this makes lipid-directed compounds promising as therapeutic options.
We assessed the antiviral effect of lauric acid, a 12-carbon medium-chain fatty acid, against DENV serotype 2 (DV2) in the presence of a stable cell line, DV2-replicon, expressing all the non-structural proteins (NS1-NS5) and a luciferase reporter.
Active viral replication in replicon cells was established by morphological examination and immunofluorescence of cells.
The MTT assay was used to determine the cytotoxicity of lauric acid revealing the LD50 of 2.
52 uM, so higher concentrations were toxic as the effect of the drug is dose-related.
The antiviral effect was tested through replicon inhibition (luciferase) assay which showed an incredible inhibition of viral RNA replication with a IC50 of 1.
70 uM and this is equivalent to antiviral mycophenolphycic acid.
The cytopathic effects, as well as a decrease in the activity of luciferase, proved the presence of viral translation and replication inhibition within the process of the treatment of the lauric acid.
These results propose that lauric acid has cytotoxic and antiviral dual effect and can be a possible inhibitor of DENV replication.
The toxicity needs to be reduced and future research is necessary to explain its molecular pathway and also to come up with the best delivery methods.
IMPORTANCE
Dengue virus (DENV) remains a significant health challenge to the world since there are no effective antiviral agents.
This work will recognize lauric acid as a possible dengue virus replication inhibitor in a model of a DV2 replicon, exhibiting antiviral action that is similar to that of mycophenolic acid.
These results support lipid-directed compounds as potential dengue antiviral targets, but more research is needed to minimize toxicity and better understand the molecular mechanism of action.
Related Results
DengueSeq: A pan-serotype whole genome amplicon sequencing protocol for dengue virus v1
DengueSeq: A pan-serotype whole genome amplicon sequencing protocol for dengue virus v1
Background Amplicon-based sequencing (PrimalSeq) was developed in response to the Zika virus epidemic due to difficulties generating complete genomes using metagenomic approaches [...
CLINICAL COURSE AND OUTCOME OF PATIENTS WITH DENGUE FEVER, DENGUE HEMORRHAGIC FEVER AND DENGUE SHOCK SYNDROME IN A TERTIARY CARE HOSPITAL IN RECENT ENDEMIC 2022
CLINICAL COURSE AND OUTCOME OF PATIENTS WITH DENGUE FEVER, DENGUE HEMORRHAGIC FEVER AND DENGUE SHOCK SYNDROME IN A TERTIARY CARE HOSPITAL IN RECENT ENDEMIC 2022
Background: Dengue fever cases have been increased almost 30-fold over last 50 years and now reaches an estimated 100 million clinically apparent infections annually. This rapid in...
Dengue spatial dynamics : the example of Northern Vietnam
Dengue spatial dynamics : the example of Northern Vietnam
Dynamique spatiale de la dengue : l'exemple du Nord Vietnam
Alors que l’épidémiologie de la dengue dans le sud du Vietnam est caractérisée par un régime d’hyper-end...
A human
ex vivo
dengue virus neutralization assay identifies priority antibodies and epitopes for vaccines and therapeutics
A human
ex vivo
dengue virus neutralization assay identifies priority antibodies and epitopes for vaccines and therapeutics
Abstract
Background
Dengue is the most prevalent arboviral disease, for which neither effective vaccines nor antivirals are ava...
Iminosugar 1-Deoxynojirimycin (DNJ) sebagai Antiviral Infeksi Virus Dengue
Iminosugar 1-Deoxynojirimycin (DNJ) sebagai Antiviral Infeksi Virus Dengue
Abstract— Dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS) caused by the DENV virus are among the global problems regarding mosquito-borne viral i...
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...
Spatial and epidemiologic features of dengue in Sabah, Malaysia
Spatial and epidemiologic features of dengue in Sabah, Malaysia
Abstract
In South East Asia, dengue epidemics have increased in size and geographical distribution in recent years. Most studies investigating de...
Role of C- reactive proteins and liver function tests in assessing the severity of dengue fever
Role of C- reactive proteins and liver function tests in assessing the severity of dengue fever
Abstract
Objective: To determine whether C-reactive protein and liver function tests can serve as severity markers for dengue fever.
Methods: The cross-sectional study ...

